Goldman Sachs
IBIO icon

Goldman Sachs’s iBio IBIO Stock Holding History

Goldman Sachs’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Buy
200,455
+243
+0.1% +$435 ﹤0.01% 5923
2026
Q1 		$380K Buy
+200,212
New +$465K ﹤0.01% 5762
2022
Q3 		– Sell
-587
Closed -$78K – 6396
2022
Q2 		$78K Buy
587
+329
+128% +$49.5K ﹤0.01% 5932
2022
Q1 		$55K Sell
258
-473
-65% -$99K ﹤0.01% 6247
2021
Q4 		$201K Buy
731
+260
+55% +$99.1K ﹤0.01% 5902
2021
Q3 		$250K Buy
471
+293
+165% +$182K ﹤0.01% 5604
2021
Q2 		$134K Buy
178
+14
+9% +$10.2K ﹤0.01% 5872
2021
Q1 		$126K Buy
164
+110
+204% +$95.8K ﹤0.01% 5776
2020
Q4 		$29K Buy
54
+29
+116% +$23.6K ﹤0.01% 5421
2020
Q3 		$26K Sell
25
-115
-82% -$167K ﹤0.01% 5238
2020
Q2 		$156K Sell
140
-54
-28% -$35.3K ﹤0.01% 4880
2020
Q1 		$103K Buy
+194
New +$74.7K ﹤0.01% 4936
2016
Q2 		– Sell
-18
Closed -$50K – 7117
2016
Q1 		$50K Buy
+18
New +$51.6K ﹤0.01% 6432

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs's IBIO Position: Q2 2026 in Review

Goldman Sachs increased its iBio (IBIO) stake by 0.12% in Q2 2026, buying an estimated $435 and bringing the position to 200,455 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #5923.

Goldman Sachs first reported a position in IBIO in Q1 2016 and has held it in 13 quarters since. The position peaked at $380K in Q1 2026. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Goldman Sachs held 200,455 shares of iBio worth $351K as of Q2 2026.
  • Goldman Sachs bought 243 iBio shares in Q2 2026, an estimated $435.
  • iBio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5923 holding.
  • Goldman Sachs first reported a position in iBio in Q1 2016 and has held it in 13 quarters since.
  • Goldman Sachs's iBio position peaked at $380K in Q1 2026.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.